Kineta's KVA12123 to Be Showcased at SITC Annual Meeting

Kineta to Present KVA12123 at SITC 2024

Kineta, Inc. (OTC: KANT), a dedicated biotechnology firm focused on pioneering immunotherapies aimed at overcoming cancer immune resistance, has exciting news to share. The company announced that its abstract on the clinical program of KVA12123 has received acceptance for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. The event is set to take place from November 6-10, 2024, and will be available both in-person and virtually.

Details on the Presentation of KVA12123

Dr. Thierry Guillaudeux, the Chief Scientific Officer of Kineta, revealed that the poster will be presented on November 8, featuring new clinical data from an ongoing Phase 1/2 trial. This trial focuses on KVA12123, Kineta's immunotherapy that blocks VISTA, administered alone and in combination with Merck's KEYTRUDA (pembrolizumab). This research highlights the potential of KVA12123 in treating advanced solid tumors, showcasing the collaboration between Kineta and leading research institutes.

Presentation Title and Authors

The title of the presentation is "A Phase 1/2 Clinical Trial of antiVISTA – KVA12123 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors." It lists a talented team of authors including Dr. Jason T. Henry and esteemed colleagues from various prestigious institutions. Their collective expertise contributes significantly to the insights shared in this trial.

Abstract Information

The abstract number is 625. Attendees can look forward to engaging discussions from 9:00 AM to 7:00 PM Central Time on the said date, hosted in the Exhibit Halls AB at the George R. Brown Convention Center. More information regarding the abstract titles will be accessible on the SITC website soon. Additionally, Kineta plans to provide access to the poster content on its website following the conference.

About Kineta and Its Mission

Kineta operates with a steadfast commitment to transforming patient lives through innovative immunotherapies. The company draws on its extensive knowledge in innate immunity, actively working on groundbreaking therapies to tackle significant challenges present in current cancer treatment methods. At present, Kineta's pipeline includes KVA12123 and a promising preclinical monoclonal antibody targeting CD27.

KVA12123: A Game Changer in Cancer Therapy

Through unique binding properties and a refined IgG1 Fc region, KVA12123 has shown impressive tumor growth inhibition both independently and in synergy with established checkpoint inhibitors in preclinical studies. This innovative approach intends to mitigate immune suppression within the tumor microenvironment, complementing traditional T cell-focused therapies. Preliminary research indicates KVA12123's potential effectiveness in a variety of cancers such as non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and more.

Recent Developments at Kineta

In early 2024, Kineta underwent a significant corporate restructuring aimed at reducing expenditures while preserving financial resources. This decision resulted in a workforce reduction and the temporary halt of enrolling new patients in the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123. Kineta is actively exploring strategic alternatives to enhance stockholder value.

Contact Information for Inquiries

For further inquiries, interested parties can reach out to Kineta's Investor Relations at info@kineta.us. The company is keen to connect and provide additional insights into their ongoing research and vision for the future.

Frequently Asked Questions

What is KVA12123?

KVA12123 is a VISTA blocking immunotherapy developed by Kineta, currently in clinical trials targeting advanced solid tumors.

When will the poster for KVA12123 be presented?

The poster will be presented on November 8, 2024, at the SITC Annual Meeting.

What phase is the clinical trial for KVA12123 currently in?

KVA12123 is currently in Phase 1/2 of clinical trials, evaluating its efficacy and safety.

Who is presenting the KVA12123 poster at SITC?

Dr. Jason Henry from Sarah Cannon Research Institute will be presenting the poster featuring new clinical data.

How can I learn more about Kineta?

You can visit their official website at www.kinetabio.com for further information regarding their research and developments.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.